Miltenyi Biotec at the EACR Virtual Congress 2021
June 9–12, 2021
Miltenyi Biotec at the EACR Virtual Congress 2021
Take your cancer research to the next level
Every year, the EACR Congress is an enormous event featuring insights into ground-breaking developments and advancements in cancer research. Also this year, we were pleased to contribute to the meeting with our Industry Symposium. The recording of our scientific talk on how cancer researchers drive target discovery to develop novel effective immunotherapies is now available here.
At Miltenyi Biotec, we are committed to support researchers with cutting-edge technologies and combine them to whole workflow solutions, comprising solid tumor dissociation, cell isolation, cell analysis, cell culture, and high-content and light sheet microscopy. Check out this web page and get inspired by the vast variety of applications and products for your cancer research.
What are you interested in?
Content
- Industry Symposium
- Highlights
- Applications
- Technologies
- Resources
Industry Symposium
Early identification of target candidates for pancreatic adenocarcinoma immunotherapy
Watch our recorded Industry Symposium to get insights into how our cancer research solutions support the discovery of novel target candidates to develop innovative therapeutic approaches.
Early identification of target candidates for pancreatic adenocarcinoma immunotherapy
Presenter: Dr. Olaf Hardt
Research and Development, Miltenyi Biotec, Germany
Abstract
Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput flow cytometry with high-content cyclic immunofluorescence for the early identification of target candidates for cellular immunotherapy. Within this symposium, we aim to guide the attendees through our most recently published scientific findings1 and related cutting-edge tools, ranging from the preparation of primary and xenografted tumor specimens to the comprehensive antigen screening and deep phenotyping.
1. Schäfer, D. et al. (2021) Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat. Commun. 12: 1453.
https://doi.org/10.1038/s41467-021-21774-4
About Dr. Olaf Hardt
Dr. Olaf Hardt is currently Senior Manager in the R&D department of Miltenyi Biotec in Bergisch Gladbach, Germany. He is heading the oncology and sample preparation departments where his focus is on immuno-oncology preclinical research, target discovery, as well as oncology related product development. He also heads the transgenic unit and animal facility. He obtained his Ph.D. at the University of Cologne, Germany, in collaboration with Miltenyi Biotec and the IBDML in Marseille, France, before he started as R&D Project Manager at Miltenyi Biotec in 2008.
Highlights
Applications
Technologies
Resources
Contact us
Do you want to get in contact with us? Send your inquiry to:
Jana Soyka, Ph.D.
Global Product Manager and Group Leader – Cancer Research
You have previously chosen International as your location.
What do you want to do?
